Artelo Biosciences Reports Key Business Updates
Artelo Biosciences, Inc., a clinical-stage pharmaceutical company committed to developing innovative treatments focused on lipid-signaling pathways, has provided a comprehensive business update along with its financial and operational results for the fiscal year ending December 31, 2024. With a mission directed towards people living with cancer, pain, and other conditions, Artelo is making transformative strides in its clinical programs.
Significant Business Highlights
Artelo continues to make progress in advancing its product pipeline, and it is noteworthy that various pivotal clinical milestones are approaching in 2025. Among the highlights:
- ART26.12: The Phase I study is on track for completion by the second quarter of 2025.
- ART27.13: The company anticipates initial data from the Phase 2 CAReS trial by the end of Q2 2025.
- ART12.11: Significant advancement has been made in preparations for human studies with this innovative oral solid dosage form expected in the second half of 2025.
Gregory D. Gorgas, President and CEO, expressed his enthusiasm regarding the rapid pace of enrollment in the Phase 1 study of ART26.12, aimed at addressing significant unmet medical needs. "The compound is the first selective FABP5 inhibitor under the firm's proprietary platform to enter human studies, with expected therapeutic potential across various applications related to lipid signaling," Gorgas stated.
Looking Ahead to 2025
In addition to ART26.12, Mr. Gorgas revealed optimism about receiving initial data from the Phase 2 CAReS study involving ART27.13. This compound aims to improve conditions related to cancer anorexia and weight loss, demonstrating a promising safety profile previously observed in the Phase 1 study.
Fiscal Year 2024 Financial Overview
As part of its year-end reporting, Artelo detailed its financial performance, outlining key metrics for the year ended December 31, 2024:
- Research and Development (R&D) Expenses: R&D expenses amounted to $6.0 million, a slight increase from $5.7 million in 2023.
- General and Administrative (G&A) Expenses: The G&A expenses were reported at $4.1 million for the year, slightly down from $4.2 million in 2023.
- Net Loss: Artelo recorded a net loss of $9.8 million, equivalent to $3.05 per basic and diluted common share. For the previous year, the net loss was $9.3 million, or $3.14 per share.
- Cash and Investments: The company reported cash and investments totaling $2.3 million as of December 31, 2024.
Innovative Therapeutics in Development
Artelo is developing several key therapeutic entities, including:
ART26.12
As the company’s lead Fatty Acid Binding Protein 5 (FABP5) inhibitor, ART26.12 aims to serve as a groundbreaking, non-opioid analgesic. The FDA has cleared it for first-in-human studies, with clinical trials targeted for chemotherapy-induced peripheral neuropathy.
ART27.13
This innovative compound serves as a once-daily oral agent, selectively activating cannabinoid receptors that could improve weight and appetite in cancer patients. Originally developed by a leading pharmaceutical company, ART27.13 aims to facilitate better quality of life measures for patients suffering from cancer-related issues.
ART12.11
Artelo's unique cocrystal formulation of cannabidiol (CBD) and tetramethylpyrazine (TMP) displays enhanced pharmacokinetics and efficacy, potentially paving the way for safer and more effective CBD pharmaceuticals well into the future.
About Artelo Biosciences
Artelo Biosciences is a company passionate about its work in developing therapies to address unmet medical needs across various disease conditions, including cancer, anxiety, and more. With a leadership team composed of experienced industry professionals, they emphasize advanced research, regulatory rigor, and a commitment to impactful therapeutics.
For more insights, interested individuals can reach out to Crescendo Communications, LLC, at 212-671-1020 or via email at ARTL@crescendo-ir.com.
Frequently Asked Questions
What is the primary focus of Artelo Biosciences?
Artelo focuses on the development of innovative therapies that modulate lipid-signaling pathways for treating various medical conditions.
When is the anticipated completion date for the Phase I study of ART26.12?
The Phase I study of ART26.12 is expected to conclude in the second quarter of 2025.
What were the R&D expenses for the fiscal year 2024?
Artelo reported R&D expenses of $6.0 million for the fiscal year ending December 31, 2024.
What is the significance of ART27.13?
ART27.13 is being evaluated as a potential treatment for cancer anorexia and weight loss, offering a new approach to improving patient appetite and body weight.
How can I find more information about Artelo Biosciences?
For further details, please visit the official Artelo Biosciences website at www.artelobio.com.
